Investigating Gastrointestinal Involvement in Post-Acute COVID-19 Syndrome

Article

Investigators found significant associations between GI-PACS and multi-system concomitant symptoms.

Patients with gastrointestinal post-acute COVID-19 syndrome (GI-PACS) are significantly more likely to develop concomitant symptoms involving multiple body systems, according to recent research.1

Investigators conducted a territory-wide survey to study the risk factors and characteristics of GI-PACS in a population based setting. A logistic regression was used to assess the association between GI-PACS and possible risk factors, as well as the odds of other symptoms concomitant with GI-PACS,

The survey included 8156 patients in Hong Kong who recovered from a COVID-19 infection between July to November 2022. The study cohort had a mean age of 43.3 and was 67.3% female. Information on date of infection, hospitalization history, vaccination status and persistent symptoms after the infection were collected.

Investigators found that 90.6% of participants reported post-acute COVID-19 syndrome of different systems after acute infection and 69.4% of subjects still experienced persistent symptoms 5 months after infection. In particular, 40.8% reported GI-PACS, of which 1 in 2 experienced symptoms such as diarrhea, constipation, abdominal pain, acid reflux, bloating, or loss of appetite.

In patients who were infected with Omicron variants of COVID-19, the odds of GI-PACS were significantly lower than with earlier variants of the virus. Those with GI-PACS were significantly more likely to develop concomitant symptoms involving multiple body systems, including respiratory, cardiovascular, neurological, cognitive, psychiatric, ophthalmological, musculoskeletal and dermatological.

Additionally, patients with GI-PACS were more likely to experience an impact in their daily functioning, which included work, study or interpersonal relationships.

“This population-based study reported possible risk factors for GI-PACS and it was the first to reveal significant associations between GI-PACS and multi-system concomitant symptoms,” the authors wrote. “These findings suggest the importance of gastrointestinal involvement in the pathogenesis of multi-system PACS, which warrants further research.”

Reference
1. Lau RI, Lau SFI, Ching JY, et al. Gastrointestinal Involvement in Post-Acute COVID-19 Syndrome: Results From A Population-Based Study of 8156 Subjects. Presented at: Digestive Disease Week; May 6-9, 2023; Chicago, IL. Poster 1060.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Image Credit: tirachard | stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.